港股異動丨中基長壽科學(0767.HK)復牌放量大漲近10% 擬1.54億元收購杭州城慧55%股權
格隆匯8月13日丨中基長壽科學(0767.HK)今日復牌放量大漲近10%,報0.67港元,盤中漲幅一度擴大至23%,成交額放大至1804萬港元,最新總市值26億港元。中基長壽科學昨晚宣佈,於2021年8月9日,公司擬向賣方勞巧然收購目標公司全部已發行股本,初步代價為人民幣約1.54億元,代價會分階段以現金及公司向賣方(或其代名人)配發及發行代價股份支付。目標公司間接持有杭州城慧55%的股權,而杭州城慧直接全資擁有城南醫院。目標集團主要經營城南醫院,一家以二級標準建立的綜合性醫院。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.